Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Private Health Management was founded in 2007 after Leslie D. Michelson and Gregg ...
Private Health Management was founded in 2007 a...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...
TG Therapeutics is a biopharmaceutical company ...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Proteon Therapeutics is working to deliver a new future for patients and families ...
Proteon Therapeutics is working to deliver a ne...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Join the National Investor Network and get the latest information with your interests in mind.